Araris Biotech collaborates with Johnson & Johnson’s Janssen Biotech to advance next-generation antibody-drug conjugates (ADCs) for cancer treatments. The partnership focuses on developing innovative therapies using ADC technology. Both companies aim to leverage their expertise to accelerate research in oncology.
Araris Biotech partners with Chugai Pharmaceuticals to develop novel antibody-drug conjugates (ADCs) using its proprietary AraLinQ™ linker-conjugation technology. Chugai provides undisclosed antibody targets for the collaboration, which includes a research agreement and potential licensing option. The Swiss biotech spin-off from PSI and ETH Zurich leverages its platform to advance tailored ADC therapies.
Roche’s Chugai Pharmaceutical partners with Zurich-based Araris Biotech to develop antibody-drug conjugates (ADCs). The collaboration secures Araris an upfront payment and up to **$780 million** in milestone-based payments. This deal marks Chugai’s first major investment as it celebrates its 100th anniversary.
Araris Biotech AG collaborates with Taiho Pharmaceutical to develop next-generation antibody-drug conjugates (ADCs) using Araris’ proprietary linker-conjugation technology. Taiho provides undisclosed oncology targets for the project, leveraging Araris’ platform to generate novel ADC candidates. Both companies specialize in oncology-focused drug development, combining expertise in biotech innovation and pharmaceutical research.
